Lead paragraph:
The Royal College of Nursing (RCN) has announced the end of its commercial relationship with Teva UK, the British arm of the global pharmaceutical giant, and removed the company from sponsorship of its upcoming migraine and headache summit scheduled for 30 October 2026. The decision follows a thorough due‑diligence review that revealed Teva’s operations have faced legal sanctions and public scrutiny, which the RCN says are incompatible with its professional values. The move has been welcomed by pro‑Palestine campaigners and raises broader questions about the role of multinational drug firms in UK healthcare.
RCN’s Decision to End Commercial Ties
In a letter addressed to Nurses for Palestine, Carmel O’Boyle, chair of the RCN ruling council, confirmed that the partnership with Teva UK is being terminated with immediate effect. “Going forward [the] RCN is ending its commercial partnership with Teva UK. Teva UK will no longer be a sponsor of the RCNi nursing leadership summit: migraine and headache services event on 30 October 2026. The event will go ahead as planned,” she stated. O’Boyle explained that the due‑diligence process uncovered several Teva activities that have attracted legal sanctions and public criticism, and that these do not align with the RCN’s commitment to patient‑centred care and ethical standards. The RCN, which represents more than 500,000 nurses across the United Kingdom, emphasised that it only wishes to maintain commercial relationships with organisations that reflect the nursing profession’s core values.
Teva’s Record of Legal and Ethical Scrutiny
Teva UK operates under the umbrella of Teva Pharmaceuticals, a company that has been one of the NHS’s largest suppliers of medicines for many years. However, the firm’s recent history is marked by a series of substantial penalties imposed by regulatory bodies. In 2024 the European Commission levied a €462.6 million fine after finding that Teva had blocked competition for its multiple‑sclerosis drug Copaxone in seven European markets for four to nine years. The following year, the US Department of Justice required Teva to pay $225 million to settle allegations of price‑fixing three separate pharmaceuticals, avoiding prosecution. In 2016, a combined settlement of $519 million was reached with the US Securities and Exchange Commission and the Department of Justice over accusations of bribery involving officials in Russia, Ukraine and Mexico. Altogether, Teva has been ordered to pay roughly £1 billion in fines and related payments over the past decade for bribery, price‑fixing and abuse of market position. These actions have attracted sustained international attention and have fuelled concerns about the company’s corporate conduct.
Responses from Campaigners and the Pharmaceutical Company
Nurses for Palestine hailed the RCN’s decision as a “major breakthrough for grassroots healthcare organising and the international boycott, divestment and sanctions movement” aimed at isolating Israel. Their spokesperson declared, “Teva has no place sponsoring professional bodies dedicated to healing, care and preserving human life.” The UK Healthcare Petitions to Royal Colleges (UKHPRC) echoed this sentiment, stating, “It is unthinkable that in this day and age healthcare organisations continue to enter into commercial relationships with companies linked to sustaining state systems accused or found by international bodies to involve grave violations of international law, including crimes against humanity, apartheid and genocide.” Conversely, Teva UK expressed disappointment, with a spokesperson noting, “We are disappointed by the RCN’s decision to end this relationship and are seeking further dialogue with the organisation. Healthcare is at its best when it remains focused on patients rather than being politicised.” The company also highlighted its longstanding partnership with the RCN and its role in supplying essential medicines to UK patients.
Implications for the NHS and Future Partnerships
The termination of the Teva‑RCN link may signal a shift in how the NHS evaluates commercial partnerships, particularly when corporate behaviour raises human‑rights concerns. While Teva continues to provide a wide range of generic and branded medicines, the RCN’s stance underscores the importance of aligning procurement and sponsorship decisions with ethical standards. Pro‑Palestine activists have now called on the Royal College of Pharmacy to follow suit, urging the cancellation of Teva’s sponsorship of its annual conference next month and the removal of its exhibition stand. This developing situation could prompt other professional bodies to reassess existing ties with pharmaceutical firms whose practices are under international scrutiny, potentially leading to a broader re‑examination of how healthcare organisations balance financial relationships with moral responsibility.
Why it Matters
The RCN’s decision marks a pivotal moment where professional nursing values intersect with geopolitical and corporate accountability. By ending its partnership with Teva UK, the RCN not only distances itself from a company tainted by significant legal violations but also sends a clear message that the nursing profession will not tolerate the politicisation of healthcare. This action may inspire greater transparency in future sponsorships and procurement processes across the NHS, encouraging stakeholders to consider the broader ethical implications of their commercial alliances. As the healthcare sector navigates these complex waters, the precedent set by the RCN could influence how other institutions safeguard the integrity of patient care and uphold the principles of compassion and equity that lie at the heart of nursing.
